NUP98

Biomea Fusion Announces Two Poster Presentations at Upcoming ASH Annual Meeting 2023

Retrieved on: 
Thursday, November 2, 2023
Trae tha Truth, ECOG, Vomiting, CYP3A4, WT, Abstract, NPM1, KMT2A, OBD, PK, DLT, TKD, Cancer, Diabetes, ORR, Clinical study design, Safety, Patient, Cohort, HSCT, SETBP1, CR, DSM-IV codes, NUP214, DOR, Dicarboxylic acid, CRi, ASH, CD135, QT interval, RFS, FLT3, Arm, Cellular, FMS, Transplant, ALL, Toxic leukoencephalopathy, Gene family, Survival, Postcholecystectomy syndrome, DS, Trial of the century, Incidence, CRC, Infrared spectroscopy correlation table, AL, Osteopathic medicine in Canada, MN1, BID, CNS, KRAS, ATD, NUP98, Society, WBC, Pharmacokinetics, CLL, Acute leukemia, Common, ITD, Toxicity, AML, Cardiovascular disease, Pharmaceutical industry, Dentistry, Vaccine, Decitabine, DLBCL

Both BMF-219 and BMF-500 were originated in-house with Biomea’s proprietary FUSION™ system platform, which discovers and designs next-generation covalent-binding small molecule product candidates.

Key Points: 
  • Both BMF-219 and BMF-500 were originated in-house with Biomea’s proprietary FUSION™ system platform, which discovers and designs next-generation covalent-binding small molecule product candidates.
  • Methods: Doses of BMF-219 are escalated independently for each indication, initially in single-subject cohorts followed by a “3 + 3” design.
  • A subsequent amendment introduced quotas for KMT2Ar (MLL1r), NPM1 and other known menin-dependent mutations: CEBP/A, MLL1-PTD, MN1, NUP98, NUP214, PICALM-AF10, SETBP1.
  • The study was initiated in July 2023 and will enroll ~110 participants at approximately 30 sites.

Biomea Fusion Reports Third Quarter 2023 Financial Results and Corporate Highlights

Retrieved on: 
Monday, October 30, 2023
Week, DLBCL, FDA, Research, Research and development, NSCLC, Trial of the century, IND, DSM-IV codes, Food, Diabetes, Health Canada, G&A, BID, CRS, KRAS, Investment, R, NUP98, Glycated hemoglobin, CLL, CD135, Disease, Clinical trial, CRC, Cancer, QT interval, Menin, MM, FLT3, Safety, PDAC, Patient, FMS, Administration, AML, Mutation, Pharmaceutical industry, Medical imaging, Cryptocurrency, Osteopathic medicine in Canada

Both studies are now open for enrollment more than a quarter ahead of schedule.

Key Points: 
  • Both studies are now open for enrollment more than a quarter ahead of schedule.
  • Finally in this quarter, we also initiated the clinical study of our second, Biomea-discovered investigational covalent inhibitor, BMF-500, a novel FLT3 inhibitor.
  • Continued to advance development candidates derived from Biomea’s proprietary FUSION™ System platform to discover novel covalently binding small molecules.
  • G&A expenses were $17.1 million for the nine months ended September 30, 2023 compared to $15.2 million for the same period in 2022.

Biomea Fusion Reports Second Quarter 2023 Financial Results and Corporate Highlights

Retrieved on: 
Monday, July 31, 2023
Momentum, CLL, PDAC, KRAS, Insulin, Food, American Diabetes Association, CRC, Diabetes, Investment, Chronic lymphocytic leukemia, ALL, Week, Menin, DLBCL, Multiple myeloma, NPM1, CD135, Bone marrow, OGTT, Type 2 diabetes, Mutation, G&A, NSCLC, B-cell lymphoma, QT interval, NUP98, AML, Hypoglycemia, HIV disease progression rates, Patient, DSM-IV codes, C-peptide, Administration, Cancer, MM, FLT3, CRS, Research and development, Commonwealth Fusion Systems, Research, R, ADA, IND, Disease, Pharmaceutical industry, Silviculture, Fine chemical, Vaccine, Medical imaging, Cryptocurrency, Glycated hemoglobin, Osteopathic medicine in Canada

Our goal at Biomea is to develop a treatment that can halt or reverse disease progression in patients with type 1 and type 2 diabetes.

Key Points: 
  • Our goal at Biomea is to develop a treatment that can halt or reverse disease progression in patients with type 1 and type 2 diabetes.
  • We look forward to continuing to evaluate BMF-219’s proposed mechanism of action and its potential therapeutic impact as this study progresses.
  • BMF-500 is an investigational oral covalent inhibitor of FLT3, designed and developed in-house, and the second investigational compound discovered by Biomea’s FUSION™ System.
  • G&A expenses were $11.4 million for the six months ended June 30, 2023 compared to $9.9 million for the same period in 2022.

BMF-219 Induces Complete Responses in Target Acute Myeloid Leukemia (AML) Patient Population

Retrieved on: 
Monday, July 24, 2023
NPM1, Acute leukemia, CYP3A4, NUP98, AML, MD, Patient, DSM-IV codes, Cancer, CR, CRS, Pharmaceutical industry

These relapsed/refractory patients had a range of prior therapies (1 to 8) and two complete responses (1 CR, 1 CRi) were observed within the first two 28-day treatment cycles with BMF-219.

Key Points: 
  • These relapsed/refractory patients had a range of prior therapies (1 to 8) and two complete responses (1 CR, 1 CRi) were observed within the first two 28-day treatment cycles with BMF-219.
  • Enrollment for Dose Level 5 has commenced to further optimize and explore the potential to improve upon these preliminary results.
  • Completion of the dose escalation for the acute leukemia cohort is anticipated later this year.
  • We are continuing to dose escalate and are looking forward to identifying the recommended Phase 2 dose within the next several months.”